Evidence map›Paper›PMID 36705064›Full record

ArticleJournal of comparative effectiveness research2023

Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain.

Ricardo Ginestal, Carlos Rubio-Terrés, Olga Durán Morán, Darío Rubio-Rodríguez, Heidi De Los Santos, Cristina Ordoñez, Isabel Sánchez-Magro

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ricardo GinestalHospital Clínico San Carlos, Neurology Department, C/ Prof Martín Lagos, 28040 Madrid, Spain.
Carlos Rubio-TerrésHEALTH VALUE, HE Department, C/ Virgen de Aránzazu, 21, 28034 Madrid, Spain.
Olga Durán MoránMerck, SLU, C/ María de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaA.
Darío Rubio-RodríguezHEALTH VALUE, HE Department, C/ Virgen de Aránzazu, 21, 28034 Madrid, Spain.
Heidi De Los SantosMerck, SLU, C/ María de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaA.ORCID 0000-0002-4630-2376
Cristina OrdoñezMerck, SLU, C/ María de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaA.
Isabel Sánchez-MagroMerck, SLU, C/ María de Molina, 40, 28006 Madrid, Spain, an affiliate of Merck KGaA.
Merck (Spain) · ESMadrid Health Service · ESHospital Clínico San Carlos · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingCladribineCost-Benefit AnalysisDimethyl FumarateHumansImmunosuppressive AgentsSpainCladribineDimethyl FumarateImmunosuppressive Agentscladribine tabletscost–effectivenessdimethyl fumaratemultiple sclerosisrelapsing-remitting multiple sclerosis

Identifiers

PMID36705064
PMCPMC10288949
OpenAlexW4318218424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.